Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2019-09-13 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of new shares, the exercise price, and the resulting total share capital. This falls under the category of share capital changes or issues. While it mentions an attachment, the text itself provides the full details of the capital increase, making it a primary announcement of a share issue rather than just a report publication announcement.
2019-09-13 English
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Share Issue/Capital Change Classification · 98% confidence The document is titled "Company announcement – No. 34/ 2019" and explicitly states that Zealand Pharma "increases its share capital as a consequence of exercise of employee warrants." It details the number of new shares issued, the proceeds, and the resulting total share capital. This action directly relates to changes in the company's capital structure due to employee stock options being exercised, which falls under the definition of Capital/Financing Update (CAP). Although it involves shares, it is not a general share issue (SHA) or a buyback (POS), but a specific consequence of financing/incentive schemes resulting in capital increase.
2019-09-13 English
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Share Issue/Capital Change Classification · 100% confidence The document is an official company announcement regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of new shares, the exercise prices, the total proceeds, and the impact on the company's total share capital. This falls directly under the definition of a share issue or capital change announcement.
2019-09-13 English
Share Issue/Capital Change 2019
Share Issue/Capital Change Classification · 98% confidence The document is a formal company announcement titled 'Zealand Pharma increases its share capital as a consequence of exercise of employee warrants'. It details the issuance of new shares due to warrant exercises, the resulting increase in share capital (DKK 59,171 divided into 59,171 new shares), and the total proceeds received. This directly relates to changes in the company's capital structure and share count. Based on the definitions, this fits best under 'Share Issue/Capital Change' (SHA), as it explicitly describes an increase in share capital resulting from employee stock options/warrants being exercised.
2019-09-13 English
Zealand Pharma completes subscription of new shares and registration of capital increase
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding the completion of a subscription of new shares and the registration of a capital increase. It details the issuance of 3,975,000 new shares, the gross proceeds, and the resulting change in total share capital. This falls directly under the category of share issuance and capital changes.
2019-09-11 English
Zealand Pharma completes subscription of new shares and registration of capital increase
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding the completion of a subscription of new shares and the registration of a capital increase. It details the issuance of 3,975,000 new shares, the gross proceeds, and the resulting change in total share capital. This falls directly under the category of share issuance and capital changes.
2019-09-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.